149 related articles for article (PubMed ID: 36994709)
1. Use of proton pump inhibitors in people taking BRAF/MEK inhibitors for metastatic melanoma.
Br J Dermatol; 2023 Mar; 188(4):e29. PubMed ID: 36994709
[No Abstract] [Full Text] [Related]
2. Pseudovitelliform maculopathy secondary to BRAF and MEK inhibitors in a patient with metastasic melanoma.
Alba-Linero C; Rocha De Lossada C; Delgado-Fernández AS; Jódar-Márquez M; Rodríguez Calvo De Mora M; Berciano-Guerrero MA
J Biol Regul Homeost Agents; 2019 September-October,; 33(5):1497-1500. PubMed ID: 31583878
[No Abstract] [Full Text] [Related]
3. Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors.
Mieczkowska K; Jacob J; Paoluzzi L; Papalezova KT; McLellan BN; Amin B
Melanoma Res; 2022 Apr; 32(2):127-129. PubMed ID: 35254335
[No Abstract] [Full Text] [Related]
4. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
5. Tumor lysis syndrome induced by BRAF/MEK double blockade in a patient with metastatic melanoma: A first case report.
Tachibana K; Ohe S; Tanaka M; Maniwa T; Isei T
J Dermatol; 2021 Jul; 48(7):e324-e326. PubMed ID: 33990995
[No Abstract] [Full Text] [Related]
6. Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.
Ibrahim T; Routier E; Weill A; Baz M; Robert C
Eur J Cancer; 2017 Sep; 82():25-26. PubMed ID: 28646770
[No Abstract] [Full Text] [Related]
7. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
[No Abstract] [Full Text] [Related]
8. The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma.
Poizeau F; Balusson F; Lemaitre F; Tron C; Pracht M; Russo D; Dinulescu M; Lesimple T; Oger E; Dupuy A
Br J Dermatol; 2023 Mar; 188(4):482-490. PubMed ID: 36760148
[TBL] [Abstract][Full Text] [Related]
9. Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma.
Marani A; Gioacchini H; Paolinelli M; Offidani A; Campanati A
Expert Opin Drug Metab Toxicol; 2023; 19(8):555-567. PubMed ID: 37659065
[TBL] [Abstract][Full Text] [Related]
10. Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.
Buchacher L; Richtig G; Dernoscheg M; Richtig E; Koch L
J Eur Acad Dermatol Venereol; 2023 May; 37(5):e605-e607. PubMed ID: 36645848
[No Abstract] [Full Text] [Related]
11. Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma.
Demarez B; Eté M; David L; Quiles N; Archier E
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e688-e689. PubMed ID: 35398936
[No Abstract] [Full Text] [Related]
12. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.
Sasaki-Saito N; Yamamura K; Hitaka T; Hirano Y; Nishihara K; Aoki M; Matsushita S
J Dermatol; 2023 Jan; 50(1):e28-e29. PubMed ID: 36217799
[No Abstract] [Full Text] [Related]
13. A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment.
Obaru C; Kimura T; Yamamura M; Kuriyama H; Kashiwada-Nakamura K; Mizuhashi S; Matsumura T; Watanabe T; Inoue T; Fukushima S
J Dermatol; 2024 Apr; 51(4):e115-e117. PubMed ID: 37927219
[No Abstract] [Full Text] [Related]
14. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
15. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
16. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
17. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
Pires da Silva I; Zakria D; Ahmed T; Trojanello C; Dimitriou F; Allayous C; Gerard C; Zimmer L; Lo S; Michielin O; Lebbe C; Mangana J; Ascierto PA; Johnson DB; Carlino M; Menzies A; Long G
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798536
[TBL] [Abstract][Full Text] [Related]
19. Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit.
Quaglino P; Fava P; Brizio M; Marra E; Rubatto M; Merli M; Tonella L; Ribero S; Fierro MT
Future Oncol; 2021 Mar; 17(7):759-761. PubMed ID: 33533662
[No Abstract] [Full Text] [Related]
20. BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma.
Carrabba NV; Siliezar PD; Laylani N; Lee AG
Can J Ophthalmol; 2023 Dec; 58(6):e251-e253. PubMed ID: 37545048
[No Abstract] [Full Text] [Related]
[Next] [New Search]
